Welcome to our dedicated page for Spero Therapeutics news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeutics stock.
Spero Therapeutics, Inc. (symbol: SPRO) is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies to combat multi-drug-resistant (MDR) bacterial infections and rare diseases. The company's mission is to bring novel treatments to patients who are in dire need of effective options against these challenging infections.
Core Business and Product Pipeline
Spero's lead product candidate is tebipenem pivoxil hydrobromide (tebipenem HBr), an oral carbapenem-class antibiotic designed to treat MDR Gram-negative infections in adults. This groundbreaking product addresses a critical need for effective oral therapies in the fight against resistant bacterial infections.
In addition to tebipenem HBr, Spero is also developing SPR720, a novel oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial (NTM) infections, a rare and often difficult-to-treat orphan disease. Furthermore, the company's pipeline includes SPR206, an investigational next-generation polymyxin product intended for intravenous administration in hospital settings to combat severe MDR Gram-negative infections.
Recent Achievements and Partnerships
Spero Therapeutics has made significant strides in its development programs. The company has secured a $95 million development milestone payable over two years as part of a licensing agreement with GSK, highlighting its potential and industry recognition. These funds are instrumental in advancing its clinical trials and bringing its innovative therapies closer to market.
Company Culture and Team
Spero Therapeutics prides itself on a culture of respect, action, collaboration, and transparency. The team comprises leaders in the field who are passionate about making a difference. This collaborative ethos ensures that every team member is not only contributing their expertise but also feeling like an integral part of the company's innovative journey.
In summary, Spero Therapeutics, Inc. is at the forefront of developing novel treatments for some of the most challenging and resistant bacterial infections. With its promising product pipeline and strong industry partnerships, the company is well-positioned to make a significant impact in the biopharmaceutical landscape.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that CEO Ankit Mahadevia, M.D. will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference from December 1-3, 2020. The presentation will take place on December 3, 2020, from 8:25 to 8:45 AM ET. Interested parties can access the live webcast on Spero's website under the 'Events and Presentations' section, with replays available for 90 days post-event. Spero focuses on developing treatments for multi-drug resistant infections and rare diseases, including its lead candidate, tebipenem HBr, which is in late-stage clinical trials.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced significant progress in its ADAPT-PO Phase 3 trial, achieving its primary endpoint for oral tebipenem HBr in treating complicated urinary tract infections. Financial results for Q3 2020 reported a net loss of $18.9 million on $4 million revenue. The company maintains cash reserves of $127.2 million, expected to fund operations into Q1 2022. Upcoming milestones include an NDA submission for tebipenem HBr by Q2 2021 and the initiation of a Phase 2a trial for SPR720 by year-end 2020. Spero also prepares for upcoming investor presentations.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on November 3, 2020, that its Compensation Committee granted stock options to purchase 30,000 shares to three new hires under the 2019 Inducement Equity Incentive Plan. These options, with an exercise price of $13.11 per share, vest over four years, incentivizing employees to enhance the company's multi-asset biopharmaceutical initiatives. Spero is focused on developing treatments for multi-drug resistant infections and rare diseases, with ongoing projects like tebipenem HBr and SPR720.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on November 5, 2020, at 4:30 p.m. EST to discuss its third quarter 2020 financial results and business updates. The company is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero's lead candidate, tebipenem HBr, showed positive results in its Phase 3 ADAPT-PO trial for complicated urinary tract infections. Additionally, Spero is advancing SPR720 for rare pulmonary diseases and SPR206 for multi-drug resistant infections in hospitals.
Spero Therapeutics (Nasdaq: SPRO) announced 15 data presentations at IDWeek™ 2020, taking place virtually from October 21-25, 2020. Key topics include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial for tebipenem HBr, which showed non-inferiority to IV ertapenem for treating complicated urinary tract infections (cUTI). Other presentations cover Spero's pipeline products, including SPR720 and SPR206. The company aims to advance antibacterials targeting multi-drug resistant infections and plans to submit a New Drug Application for tebipenem HBr in Q2 2021.
Spero Therapeutics (Nasdaq: SPRO) announced a key opinion leader call on September 30, 2020, to discuss oral tebipenem HBr for complicated urinary tract infections (cUTI). Dr. Keith Kaye will present on the treatment landscape and unmet needs. The call follows positive top-line results from Spero’s ADAPT-PO Phase 3 trial, where tebipenem HBr was shown to be statistically non-inferior to intravenous ertapenem. If approved, tebipenem HBr would be the first oral carbapenem approved in the U.S., with an NDA submission expected in Q2 2021.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced key investor presentations for September 2020, led by CEO Ankit Mahadevia. The company focuses on developing treatments for multi-drug resistant infections and rare diseases. Spero will present at the Cantor Virtual Global Healthcare Conference on September 17 and the Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit on September 23. Webcasts will be available on their website. Notably, Spero reported positive Phase 3 ADAPT-PO trial results for its lead product, tebipenem HBr, aimed at treating complicated urinary tract infections.
Spero Therapeutics, Inc. (Nasdaq: SPRO) has priced its public offering of 4,785,000 shares of common stock and 3,215,000 shares of non-voting Series D Convertible Preferred Stock at $10.00 each, aiming for gross proceeds of $80.0 million. The offering, closing around September 15, 2020, includes a 30-day option for underwriters to purchase an additional 1,200,000 shares. Proceeds will fund the development of tebipenem HBr and support general corporate purposes. The offering complies with an SEC Form S-3 registration statement.
Spero Therapeutics (Nasdaq: SPRO) announced a public offering of 8,000,000 shares of common stock, including shares of non-voting Series D Convertible Preferred Stock convertible into 1,000 shares of common stock. The net proceeds will fund the advancement of its product tebipenem HBr, aimed at filing a New Drug Application with the FDA, ongoing pipeline development, and general corporate purposes. The offering is subject to market conditions, with underwriters granted a 30-day option to purchase an additional 15% of shares at the public offering price.
Spero Therapeutics announced positive topline results from its pivotal Phase 3 trial of oral tebipenem HBr, indicating statistical non-inferiority to intravenous ertapenem for treating complicated urinary tract infections (cUTI) and acute pyelonephritis. The trial included 1,372 patients and demonstrated overall response rates of 58.8% for tebipenem HBr compared to 61.6% for ertapenem. Tebipenem HBr had a comparable safety profile, with treatment-emergent adverse events reported in about 26% of patients. Spero plans to submit a NDA to the FDA in Q2 2021.
FAQ
What is the current stock price of Spero Therapeutics (SPRO)?
What is the market cap of Spero Therapeutics (SPRO)?
What is the primary focus of Spero Therapeutics?
What are the main product candidates of Spero Therapeutics?
What is tebipenem HBr?
What is SPR720?
What is SPR206?
What recent achievement has Spero Therapeutics made?
How does Spero Therapeutics foster its company culture?
Who can I contact for investor relations at Spero Therapeutics?
Who should media inquiries be directed to at Spero Therapeutics?
What sets Spero Therapeutics apart in the biopharmaceutical industry?
